Both agentsappear to follow the lead of raltegravir (RAL) with relatively few adverse effects and minimal drug interactions. This review will evaluate the literature on DTG and identify its potential placement in the therapy of HIV
Both agentsappear to follow the lead of raltegravir (RAL) with relatively few adverse effects andminimal drug interactions. This review will evaluate the literature on DTG and identifyits potential placement in the therapy of HIV